![Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium](https://mma.prnewswire.com/media/1397131/MM87168LOGO.jpg?p=facebook)
Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium
Maria Koukiadi - Freelance Translator - freelance translator, editor and proofreader English-Greek & Greek-English | LinkedIn
![EISAI ANNOUNCES COMMENCEMENT OF OPERATIONS OF A NEW RESEARCH FACILITY AT H3 BIOMEDICINE INC., A U.S. RESEARCH SUBSIDIARY TO FACILITATE CUTTING-EDGE CANCER GENOMICS-DRIVEN DRUG DEVELOPMENT | News Release:2011 | Eisai Co., Ltd. EISAI ANNOUNCES COMMENCEMENT OF OPERATIONS OF A NEW RESEARCH FACILITY AT H3 BIOMEDICINE INC., A U.S. RESEARCH SUBSIDIARY TO FACILITATE CUTTING-EDGE CANCER GENOMICS-DRIVEN DRUG DEVELOPMENT | News Release:2011 | Eisai Co., Ltd.](https://www.eisai.com/news/images/enews201177-1.jpg)
EISAI ANNOUNCES COMMENCEMENT OF OPERATIONS OF A NEW RESEARCH FACILITY AT H3 BIOMEDICINE INC., A U.S. RESEARCH SUBSIDIARY TO FACILITATE CUTTING-EDGE CANCER GENOMICS-DRIVEN DRUG DEVELOPMENT | News Release:2011 | Eisai Co., Ltd.
![Eisai will shift U.S. HQ to New Jersey 'bio-ecosystem' in move to boost oncology, neurology portfolios | Fierce Pharma Eisai will shift U.S. HQ to New Jersey 'bio-ecosystem' in move to boost oncology, neurology portfolios | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1597159939/1.jpeg/1.jpeg?VersionId=t6UcLxDkMNVV_Myb_obXcMB302Ly1O5Z)